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Abstract 
 
Neuromedin U is a hypothalamic peptide involved in energy homeostasis and 
stress responses. The peptide, when administered intracerebroventricularly (i.c.v.), 
decreases food intake and body weight while increasing body temperature and heat 
production. We examined the effect of i.c.v. administered neuromedin U on plasma 
catecholamines with regard to the brain prostanoid using anesthetized rats. 
Neuromedin U (0.1, 0.5 and 1 nmol/animal, i.c.v.) effectively elevated plasma 
adrenaline (a maximal response was obtained at 0.5 nmol/animal), but had little effect 
on plasma noradrenaline. However, intravenously administered neuromedin U (0.5 
nmol/animal) had no effect on plasma catecholamines. Neuromedin U (0.5 
nmol/animal, i.c.v.)-induced elevation of plasma adrenaline was effectively reduced by 
intracerebroventricular pretreatments with indomethacin (an inhibitor of 
cyclooxygenase) (0.6 and 1.2 µmol/animal), furegrelate (an inhibitor of thromboxane 
A2 synthase) (0.9 and 1.8 µmol/animal) and (+)-S-145 (a blocker of prostanoid TP 
receptors) (250 and 625 nmol/animal), respectively. The neuromedin U-induced 
adrenaline response was also abolished by acute bilateral adrenalectomy. These results 
suggest that centrally administered neuromedin U evokes the secretion of adrenaline 
from the adrenal medulla by brain prostanoid TP receptor-mediated mechanisms in rats.   
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1.  Introduction 
 
Neuromedin U is a peptide initially isolated from porcine spinal cord and named 
due to its strong contractile properties in the uterus (Minamino et al., 1985). The 
peptide was later identified in the brain, spinal cord and intestine of other species 
(O’Harte et al., 1991; Kage et al., 1991; Austin et al., 1994). Rat and mouse 
neuromedin U consists of 23 amino acids and their C-terminal regions, which are 
essential for the peptide’s activity, are highly conserved compared to other species 
(Conlon et al., 1988; Minamino et al., 1988). Neuromedin U-like immunoreactivity is 
found in the spinal cord, several brain regions including the hypothalamus, pituitary 
and thyroid glands in addition to the gastrointestinal and urogenital tracts (Brighton et 
al., 2004). While several peripheral activities such as contraction of smooth muscle 
and blood vessels and hypertensive effects have been described for neuromedin U 
(Minamino et al., 1985; Sumi et al., 1987; Gardiner et al., 1990), its role in the central 
nervous system remains poorly understood.  
Neuromedin U-like immunoreactivity and mRNA in the central nervous system 
are abundant in nuclei of the brain stem and hypothalamus. Within the hypothalamus, 
neuromedin U-like immunoreactive cell bodies and mRNA expression are restricted to 
the arcuate nucleus and median eminence (Ballesta et al., 1988; Howard et al., 2000). 
The paraventricular, ventromedial and dorsomedial nuclei receive dense innervation of 
neuromedin U immunoreactive fibers (Ballesta et al., 1988). Neuromedin U receptor 
subtype 2 mRNA is also demonstrated in the hypothalamus including paraventricular 
nucleus (Guan et al., 2001). Centrally administered neuromedin U has been reported to 
decrease food intake and body weight in free-feeding rats (Howard et al., 2000; 
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Nakazato et al., 2000; Hanada et al., 2001; Ivanov et al., 2002). On the other hand, the 
peptide activates stress responses such as locomotor activity (Nakazato et al., 2000), 
non-exercise thermogenesis (Novak et al., 2006), the hypothalamo-pituitary-adrenal 
axis (Wren et al., 2002) and sympathetic nervous system (Chu et al., 2002; Sato et al., 
2007). Hypothalamic paraventricular nucleus has been shown to be a control center for 
the sympathetic nervous system (Swanson and Sawchenko, 1980) in addition to the 
hypothalamo-pituitary-adrenal axis (Herman and Cullinan, 1997). Therefore, the brain 
neuromedin U seems to associate with the regulation of both energy intake and 
expenditure. Although the energy expenditure seems to be mainly carried out by 
activation of the sympathetic nervous system, the central excitatory mechanisms are 
largely undefined. 
Recently, we reported that centrally administered stress-related neuropeptides, 
vasopressin and bombesin, elicit adrenal secretion of both adrenaline and 
noradrenaline via the brain thromboxane A2–mediated mechanisms, while centrally 
administered corticotropin-releasing factor (CRF) elicits adrenal adrenaline secretion 
and sympathetic noradrenaline release via the brain thromboxane A2– and 
prostaglandin E2-mediated mechanisms, respectively, in rats (Yokotani et al., 1995, 
2005; Okada et al., 2003). In the present study, therefore, we examined the 
mechanisms involved in the centrally administered neuromedin U-induced elevation of 
plasma catecholamines with regard to the brain prostanoids using urethane-
anesthetized rats. 
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2.  Materials and methods 
    
2.1.  Experimental procedures 
 
Male Wistar rats weighing about 350 g were maintained in an air-conditioned 
room at 22-24°C under a constant day-night rhythm for more than 2 weeks and given 
food (laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and water ad libitum. 
Under urethane anesthesia (1.0 g/kg/animal, i.p.), the femoral vein was cannulated for 
infusion of saline (1.2 ml/h), and the femoral artery was cannulated for collecting 
blood samples. In some experiments, acute bilateral adrenalectomy [plus 
hydrocortisone (5 mg/kg/animal, i.m.)] or sham-operation (plus 200 µl saline/animal, 
i.m.) was done just before these cannulations into the femoral artery and vein by an 
abdominal midline incision (Yokotani et al., 2005; Shimizu et al., 2006). After these 
procedures, the animal was placed in a stereotaxic apparatus, as shown in our previous 
papers (Yokotani et al., 1995; Shimizu et al., 2004). The skull was drilled for 
intracerebroventricular administration of test substances using a stainless-steel cannula 
(0.3 mm outer diameter). The stereotaxic coordinates of the tip of the cannula were as 
follows (in mm): AP -0.8, L 1.5, V 4.0 (AP, anterior from the bregma; L, lateral from 
the midline; V, below the surface of the brain), according to the rat brain atlas of 
Paxinos and Watson (1986). Three hours were allowed to elapse before the application 
of neuromedin U or blocking reagents. 
Neuromedin U dissolved in sterile saline was slowly injected into the right lateral 
ventricle in a volume of 10 µl/animal using a 25-µl Hamilton syringe. Each animal 
received only one dose of neuromedin U (or vehicle). Water-soluble indomethacin-Na, 
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furegrelate and (+)-S-145 dissolved in sterile saline were intracerebroventricularly 
(i.c.v.) administered in a volume of 5 µl/animal using a 10-µl Hamilton syringe. In the 
case of using blocking reagents, neuromedin U was i.c.v. administered 30 min after the 
application of indomethacin-Na and 60 min after the application of furegrelate or (+)-
S-145, due to their slightly elevating effects on the basal plasma levels of 
catecholamines. Each animal also received only one dose of blocking reagents (or 
vehicle). 
All experiments were conducted in compliance with the guiding principles for 
the care and use of laboratory animals approved by Kochi University. 
   
2.2.  Measurement of plasma catecholamines 
 
Blood samples (250 µl) were collected through an arterial catheter and were 
preserved on ice during experiments. Plasma was prepared immediately after the final 
sampling. Catecholamines in the plasma were extracted by the method of Anton and 
Sayre (1962) with a slight modification and were assayed electrochemically with high 
performance liquid chromatography (HPLC) (Shimizu et al., 2004). Briefly, after 
centrifugation, the plasma (100 µl) was transferred to a centrifuge tube containing 30 
mg of activated alumina, 2 ml of twice deionized water, 1 ml of 1.5 M Tris Buffer (pH 
8.6) containing 0.1 M disodium EDTA and 1 ng of 3,4-dihydroxybenzylamine as an 
internal standard. The tube was shaken for 10 min and the alumina was washed three 
times with 4 ml of ice-cold twice deionized water. Then, catecholamines adsorbed onto 
the alumina were eluted with 300 µl of 4% acetic acid containing 0.1 mM disodium 
EDTA. A pump (EP-300: Eicom, Kyoto, Japan), a sample injector (Model-231XL; 
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Gilson, Villiers-le-Bel, France) and an electrochemical detector (ECD-300: Eicom) 
equipped with a graphite electrode were used with HPLC. Analytical conditions were 
as follows: detector, +450 mV potential against an Ag/AgCl reference electrode; 
column, Eicompack CA-50DS, 2.1 x 150 mm (Eicom); mobile phase, 0.1 M 
NaH2PO4-Na2HPO4 buffer (pH 6.0) containing 50 mg/l disodium EDTA, 0.75 g/l 1-
octanesulfonate sodium and 15% methanol at a flow of 0.18 ml/min; injection volume, 
40 µl. The amount of catecholamines in each sample was calculated using the peak 
height ratio relative to that of 3,4-dihydroxybenzylamine. By this assay, coefficients of 
variation for intra- and inter-assay were 3.0% and 3.7%, respectively, and 0.5 pg of 
noradrenaline and adrenaline was accurately determined. 
 
2.3.  Treatment of data and statistics  
  
All values are expressed as the means±S.E.M. of the net changes above the 
respective basal values. The data were analyzed by repeated-measure analysis of 
variance (ANOVA), followed by post-hoc analysis with the Bonferroni method for 
comparing a control to all other means (Figs. 1-4). When only two means were 
compared, an unpaired Student's t-test or Welch’s t-test was used (Fig. 5). P values less 
than 0.05 were taken to indicate statistical significance. 
 
2.4.  Compounds  
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The following drugs were used: neuromedin U (Peptide Institute, Osaka, Japan); 
water-soluble indomethacin sodium trihydrate (a kind gift from Merck, Rahway, NJ, 
U.S.A); furegrelate sodium (Biomol Research Lab., Plymouth Meeting, PA, U.S.A.); 
(+)-S-145 [(+)-(1R,2S,3S,4S)-(5Z)-7-(3-[4-3H]-phenylsulphonyl-
aminobicyclo[2.2.1]hept-2-yl)hept-5-enoic acid] (a kind gift from Shionogi 
Pharmaceutical Co. Ltd., Osaka, Japan); hydrocortisone (Sigma Aldrich Fine 
Chemicals, St. Louis, MO, U.S.A.). All other reagents were of the highest grade 
available (Nacalai Tesque, Kyoto, Japan). 
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3.  Results 
 
3.1.  Effect of neuromedin U on plasma catecholamines   
 
I.c.v. administered vehicle (10 µl saline/animal) and blood sampling for 5 times 
for 60 min had no effect on the basal plasma levels of either adrenaline or 
noradrenaline (Fig. 1). 
Neuromedin U [0.1, 0.5 and 1 nmol (0.26, 1.3 and 2.6 µg)/animal, i.c.v.] 
effectively elevated plasma level of adrenaline, but a maximal response was obtained 
at 0.5 nmol/animal. The responses in each dose of neuromedin U reached a maximum 
5 min after administration of this peptide and then declined toward the basal level (Fig. 
1). On the other hand, neuromedin U (0.1, 0.5 and 1 nmol/animal, i.c.v.) slightly, but 
not significantly, elevated the plasma level of noradrenaline (Fig. 1). 
Intravenous administration of neuromedin U (0.5 nmol/animal) had no effect on 
plasma levels of both catecholamines (data not shown). 
 
3.2.  Effect of indomethacin (an inhibitor of cyclooxygenase) on the centrally 
administered neuromedin U-induced elevation of plasma catecholamines  
 
Treatments with vehicle-1 (5 µl saline/animal, i.c.v.) and vehicle-2 (10 µl 
saline/animal, i.c.v.) had no effect on the basal plasma levels of adrenaline and 
noradrenaline. Pretreatment with indomethacin [1.2 µmol (500 µg)/animal, i.c.v.] had 
no effect on the basal plasma levels of catecholamines (Fig. 2).  
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Indomethacin [0.6 and 1.2 µmol (250 and 500 µg)/animal, i.c.v.] significantly 
reduced the neuromedin U (0.5 nmol/animal, i.c.v.)-induced elevation of plasma 
adrenaline, while the reagent had no effect on the neuromedin U-induced noradrenaline 
response (Fig. 2).   
 
3.3.  Effect of furegrelate (an inhibitor of thromboxane A2 synthase) on the centrally 
administered neuromedin U-induced elevation of plasma catecholamines  
 
Treatments with vehicle-1 (5 µl saline/animal, i.c.v.) and vehicle-2 (10 µl 
saline/animal, i.c.v.) had no effect on the basal plasma levels of adrenaline and 
noradrenaline. Pretreatment with furegrelate [1.8 µmol (500 µg)/animal, i.c.v.] had no 
effect on the basal plasma levels of both catecholamines (Fig. 3).  
Furegrelate [0.9 and 1.8 µmol (250 and 500 µg)/animal, i.c.v.] reduced the 
neuromedin U (0.5 nmol/animal, i.c.v.)-induced elevation of plasma adrenaline, while 
the reagent had no effect on the neuromedin U-induced noradrenaline response (Fig. 3). 
 
3.4.  Effect of (+)-S-145 (a blocker of prostanoid TP receptors) on the centrally 
administered neuromedin U-induced elevation of plasma catecholamines  
 
Pretreatment with (+)-S-145 [625 nmol (250 µg)/animal, i.c.v.] had no effect on 
the basal plasma levels of adrenaline and noradrenaline (Fig. 4).  
(+)-S-145 [250 and 625 nmol (100 and 250 µg)/animal, i.c.v.] dose-dependently 
reduced the neuromedin U (0.5 nmol/animal, i.c.v.)-induced elevation of plasma 
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adrenaline, while the reagent had no effect on the neuromedin U-induced noradrenaline 
response (Fig. 4). 
 
3.5.  Effect of acute bilateral adrenalectomy on the centrally administered 
neuromedin U-induced elevation of plasma catecholamines  
 
The basal plasma levels of noradrenaline were not influenced by bilateral 
adrenalectomy, while the basal adrenaline level was effectively, but not significantly, 
reduced by this procedure (Fig. 5). 
Bilateral adrenalectomy abolished the neuromedin U (0.5 nmol/animal, i.c.v.)-
induced elevation of plasma adrenaline, while the procedure largely had no effect on 
the neuromedin U-induced noradrenaline response (Fig. 5).  
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4.  Discussion 
 
Plasma adrenaline is mainly secreted from adrenal medulla (adrenaline-
containing cells), while plasma noradrenaline reflects not only the release from 
sympathetic nerves but also the secretion from the adrenal medulla (noradrenaline-
containing cells) (Verhofstad et al., 1985; Edwards et al., 1996; Suzuki and Kachi, 
1996; Vollmer et al., 2000; Yamaguchi-Shima et al., 2007). In the present study, i.c.v. 
administered neuromedin U elevated plasma adrenaline but had little effect on plasma 
noradrenaline in rats. Since intravenously administered neuromedin U had no effect on 
the plasma catecholamines, the peptide seems to act on the central nervous system, 
thereby activating the central adrenomedullary outflow in rats. 
We previously reported that central pretreatment with indomethacin or 
ketoprofen (inhibitors of cyclooxygenase) attenuates the i.c.v. administered CRF-, 
vasopressin-, bombesin- and histamine-induced elevation of plasma catecholamines in 
rats (Okuma et al., 1996; Yokotani et al., 2001; Okada et al., 2003; Shimizu et al., 
2006). Since prostanoids (prostaglandins and thromboxane A2) generated by several 
enzymes including cyclooxygenase have been demonstrated to act as a neuromediator 
and/or neuromodulator in the brain’s actions including cardiovascular function (Wood 
et al., 1993; Zhang et al., 2003) and regulation of hormone secretion (Bernardini et al., 
1989; Reimsnider and Wood, 2006), the brain prostanoids seem to be involved in these 
substances-induced activation of the sympatho-adrenomedullary outflow. In the 
present study, the adrenaline response induced by i.c.v. administered neuromedin U 
was attenuated by central pretreatment with indomethacin, suggesting the involvement 
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of brain prostanoids in the neuromedin U-induced activation of adrenomedullary 
outflow in rats. 
Previously, we reported that microinjection of thromboxane A2 mimetic into the 
hypothalamic paraventricular nucleus predominantly elevates plasma adrenaline by 
activation of the brain prostanoid TP receptors in rats (Murakami et al., 2002). 
Furthermore, brain thromboxane A2 is involved in the centrally administered CRF-, 
vasopressin-, bombesin- and histamine-induced secretion of adrenaline from the 
adrenal medulla in rats (Okada et al., 2003; Yokotani et al., 2005; Shimizu et al., 2006). 
Recently, Yalcin and Savci (2004) reported that activation of the brain prostanoid TP 
receptors elevates plasma adrenaline in addition to its pressor effect. In the present 
study, central pretreatments with furegrelate [an inhibitor of thromboxane A2 synthase 
(Gorman et al., 1983)] and (+)-S-145 [a blocker of prostanoid TP receptors (Hanasaki 
and Arita, 1988; Mihara et al., 1989)] effectively attenuated the elevation of plasma 
adrenaline induced by i.c.v. administered neuromedin U, respectively. These lines of 
evidence suggest that centrally administered neuromedin U activates the 
adrenomedullary outflow by brain prostanoid TP receptor-mediated mechanisms in rats. 
Although plasma adrenaline originates exclusively from the adrenal medulla, the 
contribution of the extramedullary chromaffin tissues cannot be excluded. Previously, 
we reported that bilateral adrenalectomy abolished the elevation of plasma adrenaline 
induced by i.c.v. administered CRF-, bombesin-, vasopressin- and histamine in rats 
(Okada et al., 2003; Yokotani et al., 2005; Shimizu et al., 2006). These results indicate 
that these substances evoke the secretion of adrenaline from the adrenal medulla. In the 
present study, bilateral adrenalectomy abolished the neuromedin U-induced elevation 
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of plasma adrenaline, suggesting that centrally administered neuromedin U activates 
the secretion of adrenaline from the adrenal medulla in rats. 
The hypothalamus, especially the paraventricular nucleus, has been considered to 
be the control center of the sympatho-adrenomedullar outflow (Swanson and 
Sawchenko, 1980; Jansen et al., 1995; Kenney et al., 2003). Neuromedin U directly 
activates the hypothalamic paraventricular nucleus in vitro and in vivo (Niimi et al., 
2001; Ozaki et al., 2002; Qiu et al., 2003). Furthermore, this nucleus receives dense 
innervation of neuromedin U-immunoreactive fibers (Ballesta et al., 1988; Brighton et 
al., 2004). Neuromedin U receptor subtype 2, predominantly expressed in the central 
nervous system, is also abundantly found in the paraventricular nucleus (Howard et al., 
2000; Graham et al., 2003; Brighton et al., 2004). These lines of evidence further 
suggest a role of brain neuromedin U in the central activation of adrenomedullary 
outflow in rats. 
Recently, i.c.v. administered neuromedin U (0.05 and 0.5 nmol) has been shown 
to increase the mean blood pressure, heart rate and plasma noradrenaline in conscious 
rats (Chu et al., 2002). The reason for the difference in the neuromedin U-induced 
elevation of plasma catecholamines seems to be due to the experimental conditions, 
because many reflex responses are involved in conscious animals. In addition, 
microinjection of neuromedin U (5, 10 and 50 pmol) into the nucleus tractus solitarius 
decreased the mean blood pressure and heart rate in urethane-anesthetized rat (Tsubota 
et al., 2003). The nucleus tractus solitarius is the site of termination of the 
cardiovascular afferent fibers of baroreceptors and distribution of neuromedin U-
containing neurons has been demonstrated (Ballesta et al., 1988). Up-regulation of c-
Fos expression by i.c.v. administered neuromedin U has been reported in the nucleus 
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tractus solitarius in addition to the hypothalamic paraventricular nucleus (Ivanov et al., 
2002). In the present study, the effect of a larger dose of neuromedin U (1 nmol) on the 
plasma adrenaline was smaller than that of neuromedin U (0.5 nmol). The results 
suggest a possibility that a large dose of neuromedin U activates nucleus tractus 
solitarius, thereby inhibiting the activity of the paraventricular nucleus and/or 
sympathetic preganglionic neurons in the spinal cord, since the nucleus tractus 
solitarius projects to the hypothalamic paraventricular nucleus and spinal cord, thereby 
modulating their activities (Loewy and Burton, 1978; Ter Horst et al., 1989).   
In summary, we demonstrated here that centrally administered neuromedin U 
evokes the secretion of adrenaline from the adrenal medulla by brain prostanoid TP 
receptor-mediated mechanisms in rats.  
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Legends to figures 
 
Fig. 1. Effect of neuromedin U on plasma catecholamines. ∆Adrenaline and 
∆Noradrenaline: increments of adrenaline and noradrenaline above the basal. Arrow 
indicates the administration of vehicle (saline 10 µl/animal, i.c.v.) or neuromedin U 
(0.1, 0.5 and 1 nmol/animal, i.c.v.). Each point represents the mean±S.E.M. 
*Significantly different from the vehicle-treated group with the Bonferroni method 
[adrenaline; at 5 min, F(3,24)=7.76, P<0.017: noradrenaline; at 30 min, F(3,23)=6.59, 
P<0.017]. The actual values for adrenaline and noradrenaline at 0 min were 414±51 
and 315±23 pg/ml (n=28), respectively.   
 
Fig. 2. Effect of indomethacin (an inhibitor of cyclooxygenase) on the centrally 
administered neuromedin U-induced elevation of plasma catecholamines.  
Indomethacin (0.6 and 1.2 µmol/animal, i.c.v.) or vehicle-1 (5 µl saline/animal, i.c.v.) 
was administered 30 min before the administration of neuromedin U (0.5 nmol/animal, 
i.c.v.) or vehicle-2 (10 µl saline/animal, i.c.v.). Arrows indicate the 
intracerebroventricular administrations of indomethacin/vehicle-1 and neuromedin 
U/vehicle-2. *Significantly different from the vehicle-1- and neuromedin U-treated 
group with the Bonferroni method [adrenaline; at 5 min, F(2,14)=5.22, P <0.025]. 
Other conditions were the same as those of Fig. 1. The actual values for adrenaline and 
noradrenaline at 0 min were 316±53 and 413±49 pg/ml in the vehicle-1-pretreated 
group (n=12); 411±68 and 246±38 pg/ml in the indomethacin (0.6 µmol/animal)-
pretreated group (n=5); 390±157 and 261±88 pg/ml in the indomethacin (1.2 
µmol/animal)-pretreated group (n=10), respectively.   
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Fig. 3. Effect of furegrelate (an inhibitor of thromboxane A2 synthase) on the centrally 
administered neuromedin U-induced elevation of plasma catecholamines. Furegrelate 
(0.9 and 1.8 µmol/animal, i.c.v.) or vehicle-1 (5 µl saline/animal, i.c.v.) was 
administered 60 min before the administration of neuromedin U (0.5 nmol/animal, 
i.c.v.) or vehicle-2 (10 µl saline/animal, i.c.v.). *Significantly different from the 
vehicle-1- and neuromedin U-treated group with the Bonferroni method [adrenaline: at 
5 min, F(2,15)=7.40, P<0.025; at 10 min, F(2,14)=4.44, P<0.025]. Other conditions 
were the same as those of Figs. 1 and 2. The actual values for adrenaline and 
noradrenaline at 0 min were 351±59 and 416±45 pg/ml in the vehicle-1-pretreated 
group (n=12); 408±77 and 322±85 pg/ml in the furegrelate (0.9 µmol/animal)-
pretreated group (n=6); 377±113 and 467±45 pg/ml in the furegrelate (1.8 
µmol/animal)-pretreated group (n=12), respectively.   
 
Fig. 4. Effect of (+)-S-145 (a blocker of prostanoid TP receptors) on the centrally 
administered neuromedin U-induced elevation of plasma catecholamines. (+)-S-145 
(250 and 625 nmol/animal, i.c.v.) or vehicle-1 (5 µl saline/animal, i.c.v.) was 
administered 60 min before the administration of neuromedin U (0.5 nmol/animal, 
i.c.v.) or vehicle-2 (10 µl saline/animal, i.c.v.). *Significantly different from the 
vehicle-1- and neuromedin U-treated group with the Bonferroni method [adrenaline; at 
5 min, F(2,17)=15.83, P<0.025]. Vehicle-1-treated groups were cited from Fig. 3. 
Other conditions were the same as those in Figs. 1-3. The actual values for adrenaline 
and noradrenaline at 0 min were 112±24 and 197±38 pg/ml in the (+)-S-145 (250 
28 
nmol/animal)-pretreated group (n=7); 98±22 and 234±52 pg/ml in the (+)-S-145 (625 
nmol/animal)-pretreated group (n=11), respectively.   
 
Fig. 5. Effect of acute bilateral adrenalectomy on the centrally administered 
neuromedin U-induced elevation of plasma catecholamines. Acute bilateral 
adrenalectomy [plus hydrocortisone (5 mg/kg/animal, i.m.)] or sham-operation (plus 
200 µl saline/animal, i.m.) was done 3 hr before the application of neuromedin U (0.5 
nmol/animal, i.c.v.). Arrow indicates the administration of neuromedin U. 
*Significantly different from the sham-operated group with an unpaired Student's t-test 
or Welch’s t-test [adrenaline; at 5 min, F(4,5)=16.09, P<0.05, at 10 min, F(4,5)=9.22, 
P<0.05, at 30 min, F(4,5)=7.63, P<0.05 : noradrenaline; at 30 min, F(4,5)=1.09, 
P<0.05]. Other conditions were the same as those in Figs. 1-4. The actual values for 
adrenaline and noradrenaline at 0 min were 164±55 and 193±37 pg/ml in sham-
operated group (n=5) and 86±78 and 145±38 pg/ml in bilateral adrenalectomized 
group (n=6), respectively.   
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